Allergy and diseases caused or complicated by allergy, such as asthma, or diseases with symptoms which mimic allergy, are among the most widespread and costly health problems in the world. Phadia has made testing for allergy safe, simple, and accurate with
groundbreaking technology that puts the latest generation of automated
ImmunoCAP instrumentation into laboratories of every size, including those in physician offices.
Detection of immunoglobulin E (IgE) antibodies and determination of specific allergens allow for better outcomes and increased quality of life for allergy patients. To be reliable, the testing system used to detect allergy must be standardized. Phadia allergy test systems, along with all their components, are standardized against World Health Organization reference preparations for reproducible, reliable results.
Advanced technology
ImmunoCAP® Specific IgE assays are the first to be FDA cleared for the quantitative measurement of specific IgE
-
The most significant feature of ImmunoCAP technology is the extremely high binding capacity of the cellulose polymer sponge. This capacity, along with extensive quality control measures, excellent allergen and reagent source materials, and calibration to WHO reference preparations, results in both high sensitivity and high specificity for assays based on this technology. In addition, the structural design of ImmunoCAP allows for automation and thorough elimination of unbound nonspecific material in the reaction complex, resulting in highly reproducible, accurate, and quantitative results.